Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial

Vincent Meininger; Angela Genge; Leonard van den Berg; Wim Robberecht; Albert Ludolph; Adriano Chiò; Seung Kim; P Nigel Leigh; Matt Kiernan; Jeremy Shefner; Claude Desnuelle; Karen Morrison; Susanne Petri; Diane Boswell; Jane Temple; Rajat Mohindra; Matt Davies; Jonathan Bullman; Paul Rees; Arseniy Lavrov; William Camu; Jerzy Daniluk; Anne Dekker; Alain Destée; Matthew Devine; Stephen Dewall; Johannes Dorst; Giuseppe Fuda; Harutoshi Fujimura; Andreas Funke; Torsten Grehl; Julian Grosskreutz; Usha Gungabissoon; Rob Henderson; Peggy Ho; William Huynh; Saiju Jacob; Raul Juntas-Morales; Byung-Jo Kim; Xenia Kobeleva; Sonja Koerner; Stephen Kolb; Katja Kollewe; Lawrence Korngut; Géraldine Lautrette; Amy Lee; Anthony Lynch; Rami Massie; Genevieve Matte; Darryl Menezes; Stefano Milleri; Linda Nichols; Kazutoshi Nishiyama; Mieko Ogino; Chris Parkinson; Pierre-François Pradat; Tino Prell; Jeffrey Price; Eleanor Ramsey; Thomas Ringer; Kristiana Salmon; Christen Shoesmith; Marie Helene Soriani; Marloes Stam; Erik Steinberg; Rob Stubbs; Herman Sullivan; Philip van Damme; Michael van Es; Anne Visser; Mary Lou Watson; Andrea Sylvia Winkler; Lorne Zinman; Margie Zoing

doi:10.1016/S1474-4422(16)30399-4

Back

Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial

Journal article

Peer reviewed

Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial

Vincent Meininger, Angela Genge, Leonard van den Berg, Wim Robberecht, Albert Ludolph, Adriano Chiò, Seung Kim, P Nigel Leigh, Matt Kiernan, Jeremy Shefner, …

The Lancet Neurology, Vol.16(3), pp.208 - 216

03/2017

DOI: https://doi.org/10.1016/S1474-4422(16)30399-4

PMID: 28139349

Abstract

Neurite outgrowth inhibitor A (Nogo-A) is thought to have a role in the pathophysiology of amyotrophic lateral sclerosis (ALS). A monoclonal antibody against Nogo-A showed a positive effect in the SOD1G93A mouse model of ALS, and a humanised form of this antibody (ozanezumab) was well tolerated in a first-in-human trial. Therefore, we aimed to assess the safety and efficacy of ozanezumab in patients with ALS.

Files and links (1)

url

Find in HALView

Metrics

1 Record Views

See more details

Details

Title: Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial
Creators - without role: Vincent Meininger - Générale de Santé
Angela Genge - Montreal Neurological Institute and Hospital
Leonard van den Berg - Heidelberg University
Wim Robberecht - KU Leuven
Albert Ludolph - Helmholtz-Institute Ulm
Adriano Chiò - University of Turin
Seung Kim - Hanyang University Medical Center
P Nigel Leigh - Brighton and Sussex Medical School
Matt Kiernan - University of Sydney
Jeremy Shefner - Barrow Neurological Institute
Claude Desnuelle - Institut de Biologie Valrose
Karen Morrison - University of Birmingham
Susanne Petri - Medizinische Hochschule Hannover
Diane Boswell - GlaxoSmithKline
Jane Temple - GlaxoSmithKline
Rajat Mohindra - GlaxoSmithKline
Matt Davies - GlaxoSmithKline
Jonathan Bullman - GlaxoSmithKline
Paul Rees - GlaxoSmithKline
Arseniy Lavrov - GlaxoSmithKline
William Camu - Université de Montpellier, Institut des Neurosciences de Montpellier - INM
Jerzy Daniluk
Anne Dekker
Alain Destée
Matthew Devine - University of Sydney
Stephen Dewall
Johannes Dorst
Giuseppe Fuda
Harutoshi Fujimura
Andreas Funke
Torsten Grehl
Julian Grosskreutz
Usha Gungabissoon
Rob Henderson
Peggy Ho
William Huynh
Saiju Jacob
Raul Juntas-Morales - Université de Montpellier, Institut des Neurosciences de Montpellier - INM
Byung-Jo Kim
Xenia Kobeleva
Sonja Koerner
Stephen Kolb
Katja Kollewe
Lawrence Korngut
Géraldine Lautrette - Hôpital Universitaire Dupuytren
Amy Lee
Anthony Lynch
Rami Massie
Genevieve Matte
Darryl Menezes
Stefano Milleri
Linda Nichols
Kazutoshi Nishiyama
Mieko Ogino
Chris Parkinson
Pierre-François Pradat
Tino Prell
Jeffrey Price
Eleanor Ramsey
Thomas Ringer
Kristiana Salmon
Christen Shoesmith
Marie Helene Soriani
Marloes Stam
Erik Steinberg
Rob Stubbs - KU Leuven
Herman Sullivan
Philip van Damme - KU Leuven
Michael van Es
Anne Visser - Medizinische Hochschule Hannover
Mary Lou Watson
Andrea Sylvia Winkler
Lorne Zinman
Margie Zoing
Publication Details: The Lancet Neurology, Vol.16(3), pp.208 - 216
Identifiers: 9934884409311
Academic Unit: Institut des Neurosciences de Montpellier - INM
Language: English
Resource Type: Journal article
Local Fields: hal-01785450